Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Chem Inf Model ; 64(6): 1984-1995, 2024 Mar 25.
Article in English | MEDLINE | ID: mdl-38472094

ABSTRACT

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main Protease (Mpro) is an enzyme that cleaves viral polyproteins translated from the viral genome and is critical for viral replication. Mpro is a target for anti-SARS-CoV-2 drug development, and multiple Mpro crystals complexed with competitive inhibitors have been reported. In this study, we aimed to develop an Mpro consensus pharmacophore as a tool to expand the search for inhibitors. We generated a consensus model by aligning and summarizing pharmacophoric points from 152 bioactive conformers of SARS-CoV-2 Mpro inhibitors. Validation against a library of conformers from a subset of ligands showed that our model retrieved poses that reproduced the crystal-binding mode in 77% of the cases. Using models derived from a consensus pharmacophore, we screened >340 million compounds. Pharmacophore-matching and chemoinformatics analyses identified new potential Mpro inhibitors. The candidate compounds were chemically dissimilar to the reference set, and among them, demonstrating the relevance of our model. We evaluated the effect of 16 candidates on Mpro enzymatic activity finding that seven have inhibitory activity. Three compounds (1, 4, and 5) had IC50 values in the midmicromolar range. The Mpro consensus pharmacophore reported herein can be used to identify compounds with improved activity and novel chemical scaffolds against Mpro. The method developed for its generation is provided as an open-access code (https://github.com/AngelRuizMoreno/ConcensusPharmacophore) and can be applied to other pharmacological targets.


Subject(s)
COVID-19 , SARS-CoV-2 , Humans , Small Molecule Libraries/pharmacology , Pharmacophore , Consensus , Viral Nonstructural Proteins/chemistry , Protease Inhibitors/pharmacology , Protease Inhibitors/chemistry , Molecular Docking Simulation , Antiviral Agents/pharmacology , Antiviral Agents/chemistry
2.
ACS Omega ; 8(33): 30694-30704, 2023 Aug 22.
Article in English | MEDLINE | ID: mdl-37636945

ABSTRACT

G9a is a histone-lysine methyltransferase that performs the mono- and dimethylation of lysine 9 at histone 3 of the nucleosome. It belongs to the SET PKMT family, and its methylations are related to promoter repression and activation. G9a is a promising epigenetic target. Despite the fact that there are several G9a inhibitors under development, there are no compounds in clinical use due to adverse in vivo ADMET (absorption, distribution, metabolism, excretion, and toxicity) issues. The goal of this study is to discuss the exploration, characterization, and analysis of the chemical space of 409 G9a inhibitors reported in a large public database. Exploring the chemical space of the inhibitors led to the quantification of their structural diversity based on molecular scaffolds and structural fingerprints of different designs. As part of the analysis, the G9a inhibitors were compared with commercial libraries focused on epigenetic targets. The findings of this work will help in the development of, in a follow-up study, predictive models to identify G9a inhibitors. This study also points out the relevance of screening commercial libraries to expand the epigenetic relevant chemical space, in particular, G9a inhibitors.

SELECTION OF CITATIONS
SEARCH DETAIL
...